|
1
|
Pozo AL, Godfrey EM and Bowles KM:
Splenomegaly: Investigation, diagnosis and management. Blood Rev.
23:105–111. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Curovic Rotbain E, Lund Hansen D,
Schaffalitzky de Muckadell O, Wibrand F, Meldgaard Lund A and
Frederiksen H: Splenomegaly-diagnostic validity, work-up, and
underlying causes. PLoS One. 12(e0186674)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lv Y, Lau WY, Li Y, Deng J, Han X, Gong X,
Liu N and Wu H: Hypersplenism: History and current status. Exp Ther
Med. 12:2377–2382. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bagrodia N, Button AM, Spanheimer PM,
Belding-Schmitt ME, Rosenstein LJ and Mezhir JJ: Morbidity and
mortality following elective splenectomy for benign and malignant
hematologic conditions: Analysis of the American college of
surgeons national surgical quality improvement program data. JAMA
Surg. 149:1022–1029. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Luu S, Spelman D and Woolley IJ:
Post-splenectomy sepsis: Preventative strategies, challenges, and
solutions. Infect Drug Resist. 12:2839–2851. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sinwar PD: Overwhelming post splenectomy
infection syndrome-review study. Int J Surg. 12:1314–1316.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Paulino AC and Reddy SP: Splenic
irradiation in the palliation of patients with lymphoproliferative
and myeloproliferative disorders. Am J Hosp Palliat Care. 13:32–35.
1996.PubMed/NCBI View Article : Google Scholar
|
|
8
|
McFarland JT, Kuzma C, Millard FE and
Johnstone PA: Palliative irradiation of the spleen. Am J Clin
Oncol. 26:178–183. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Soldić Z, Murgić J, Jazvić M, Radić J,
Bolanca A, Stancić V and Kusić Z: Splenic irradiation in
hematologic malignancies and other hematologic disorders-single
institution experience. Acta Clin Croat. 50:29–35. 2011.PubMed/NCBI
|
|
10
|
Gratwohl A, Hermans J, van Biezen A,
Arcese W, Debusscher L, Ernst P, Ferrant A, Frassoni F, Gahrton G,
Iriondo A, et al: Splenic irradiation before bone marrow
transplantation for chronic myeloid leukaemia. Chronic leukaemia
working party of the European group for blood and marrow
transplantation (EBMT). Br J Haematol. 95:494–500. 1996.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Common Terminology Criteria for Adverse
Events (CTCAE), version 5.0. Washington, DC: US Department of
Health and Human Services. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
Accessed February 28, 2021.
|
|
12
|
Kriz J, Micke O, Bruns F, Haverkamp U,
Mücke R, Schäfer U, Seegenschmiedt H, Müller RP and Eich HT:
Radiotherapy of splenomegaly: A palliative treatment option for a
benign phenomenon in malignant diseases. Strahlenther Onkol.
187:221–224. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zaorsky NG, Williams GR, Barta SK, Esnaola
NF, Kropf PL, Hayes SB and Meyer JE: Splenic irradiation for
splenomegaly: A systematic review. Cancer Treat Rev. 53:47–52.
2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
de la Pinta C, Fernández Lizarbe E,
Montero Luis Á, Domínguez Rullán JA and Sancho García S: Treatment
of symptomatic splenomegaly with low doses of radiotherapy:
Retrospective analysis and review of the literature. Tech Innov
Patient Support Radiat Oncol. 3-4:23–29. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bruns F, Bremer M, Dettmer A and Janssen
S: Low-dose splenic irradiation in symptomatic congestive
splenomegaly: Report of five cases with literature data. Radiat
Oncol. 9(86)2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu MT, Hsieh CY, Chang TH, Lin JP and
Huang CC: Radiotherapy for hypersplenism from congestive
splenomegaly. Ann Saudi Med. 24:198–200. 2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Paulsen Ø, Laird B, Aass N, Lea T, Fayers
P, Kaasa S and Klepstad P: The relationship between
pro-inflammatory cytokines and pain, appetite and fatigue in
patients with advanced cancer. PLoS One.
12(e0177620)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Weinmann M, Becker G, Einsele H and
Bamberg M: Clinical indications and biological mechanisms of
splenic irradiation in chronic leukaemias and myeloproliferative
disorders. Radiother Oncol. 58:235–246. 2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gangat N, Caramazza D, Vaidya R, George G,
Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, et
al: DIPSS plus: A refined dynamic international prognostic scoring
system for primary myelofibrosis that incorporates prognostic
information from karyotype, platelet count, and transfusion status.
J Clin Oncol. 29:392–397. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tremblay D, Schwartz M, Bakst R, Patel R,
Schiano T, Kremyanskaya M, Hoffman R and Mascarenhas J: Modern
management of splenomegaly in patients with myelofibrosis. Ann
Hematol. 99:1441–1451. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Verstovsek S, Mesa RA, Gotlib J, Levy RS,
Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver
RT, et al: A double-blind, placebo-controlled trial of ruxolitinib
for myelofibrosis. N Engl J Med. 366:799–807. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Harrison C, Kiladjian JJ, Al-Ali HK,
Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS,
Levy R, Knoops L, et al: JAK inhibition with ruxolitinib versus
best available therapy for myelofibrosis. N Engl J Med.
366:787–798. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Talpaz M and Kiladjian JJ: Fedratinib, a
newly approved treatment for patients with myeloproliferative
neoplasm-associated myelofibrosis. Leukemia. 35:1–17.
2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Patel AA and Odenike O: The next
generation of JAK inhibitors: An update on fedratinib, momelotonib,
and pacritinib. Curr Hematol Malig Rep. 15:409–418. 2020.PubMed/NCBI View Article : Google Scholar
|
